Key result
Synthetic isoquinoline derivative UK.2371 lacks reported efficacy or safety data versus placebo for respiratory illnesses.
Why the study?
Does a synthetic isoquinoline derivative (UK.2371) prevent respiratory illnesses in male students?
RCT (n=264)
randomly allocated
Does a synthetic isoquinoline derivative (UK.2371) prevent respiratory illnesses in male students?
Answers are grounded in this paper and cite their sources.
May prompt reevaluation of mitral valve timing assumptions; leaves open validation and prosthetic design implications.
JOHN WRIGHT This has been evolved with a modified pulse duplicator and the use of a hot film probe for measuring velocity, direction, and turbulence.Many of the commercially available mitral valve prostheses are being investigated for their flow characteristics.In addition, efficiency is being examined and some unusual findings point to the possibility of a hydraulic ram effect in the normal mitral valve that allows opening to commence before the end of ventricular systole. TRIAL OF A NEW ANTI-MYXOVIRUS COMPOUNDJ. E. STARK Two hundred and sixty-four male students living in a hall of residence volunteered to take part in the trial and were randomly allocated into two groups.One group received a synthetic isoquinoline derivative (UK.2371) daily in divided doses and the other group received identical placebo tablets.During the five weeks of the trial tablets were distri- buted daily and volunteers were asked to return any tablets which had not been taken.As an additional guide to tablet acceptance a small quantity of isoniazid was incorporated into some active and placebo tablets and urine samples collected at appropriate times were tested for isoniazid derivatives.Volunteers were questioned each week about their health and were asked to report all respiratory and other illnesses.All respiratory illnesses were fully investigated for virus and mycoplasma infections.Full toxicity studies were carried out.
No takes yet. Share an insight, caveat, or question.
Dyde et al. (1969) conducted an RCT in respiratory illnesses (n=264). synthetic isoquinoline derivative (UK.2371) vs. placebo was evaluated on respiratory and other illnesses. A randomized trial evaluated a synthetic isoquinoline derivative (UK.2371) versus placebo for respiratory illnesses in 264 male students, but the abstract reports no efficacy or safety results.
Synapse has enriched 10 related papers. Consider them for comparative context: